AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28249107 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control condition
Number of subjects: 47
Study 25581207 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 329
Study 25581207 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 329
Study 22488783 — intervention group
Group type: EXPERIMENTAL
Intervention: Early PCI (within 24 hours of presentation)
Number of subjects: 13762
Study 22488783 — intervention group
Group type: COMPARATOR
Intervention: Delayed PCI (more than 24 hours after presentation)
Number of subjects: 13762
Study 21332653 — intervention group
Group type: EXPERIMENTAL
Intervention: 100‐min infusion of gemcitabine
Number of subjects: 32
Study 21332653 — intervention group
Group type: COMPARATOR
Intervention: 30‐min infusion of gemcitabine
Number of subjects: 32
Study 21332653 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged infusion after week 1
Number of subjects: 32
Study 20178214 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage in saline water at 37 degrees C
Number of subjects: 36
Study 20178214 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage inside roots of extracted human teeth immersed in saline water at 37 degrees C
Number of subjects: 36
Study 20178214 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage in mineral oil at 37 degrees C
Number of subjects: 36
Study 20178214 — intervention group
Group type: EXPERIMENTAL
Intervention: Storage in dry conditions at 37 degrees C
Number of subjects: 36
Study 20178214 — intervention group
Group type: EXPERIMENTAL
Intervention: DT Light Post, GC Post, FRC Postect Plus
Number of subjects: 36
Study 16915025 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated physical activity (4 x 10‐min walks at 50% of VO2peak)
Number of subjects: 21
Study 16915025 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous physical activity (40‐min walk at 50% of VO2peak)
Number of subjects: 21
Study 16915025 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 21
Study 15060511 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine 100 mg orally once daily for 4 days
Number of subjects: 10
Study 11755894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL 8‐2698 (6.0 mg)
Number of subjects: 0
Study 11755894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL 8‐2698 (0.5 to 3.0 mg)
Number of subjects: 0
Study 11755894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL 8‐2698 (> or = 3.0 mg)
Number of subjects: 0
Study 11755894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL 8‐2698 (lower doses)
Number of subjects: 0
Study 11755894 — intervention group
Group type: EXPERIMENTAL
Intervention: ADL 8‐2698
Number of subjects: 0
Study 9385475 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan 40 mg
Number of subjects: 501
Study 9385475 — intervention group
Group type: COMPARATOR
Intervention: Lisinopril 2.5 mg
Number of subjects: 501
Study 7953037 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial intervention delivered by trained community psychiatric nurses (CPNs)
Number of subjects: 48
Study 7953037 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 48
Study 3617239 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intramuscular and oral estrogen treatment (ESTR, n = 39)
Number of subjects: 80
Study 3617239 — intervention group
Group type: COMPARATOR
Intervention: Orchidectomy (ORX, n = 41)
Number of subjects: 80
Study 28643356 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab
Number of subjects: 16
Study 28643356 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 27439527 — intervention group
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir (LPV/r)
Number of subjects: 451
Study 27439527 — intervention group
Group type: COMPARATOR
Intervention: Nevirapine (NVP)
Number of subjects: 451
Study 25111732 — intervention group
Group type: EXPERIMENTAL
Intervention: Ownership information taught to children
Number of subjects: 0
Study 25111732 — intervention group
Group type: EXPERIMENTAL
Intervention: Labeling information taught to children
Number of subjects: 0
Study 25111732 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults tracking object identity
Number of subjects: 0
Study 25111732 — intervention group
Group type: EXPERIMENTAL
Intervention: Unrelated dimension (preference)
Number of subjects: 0
Study 22211444 — intervention group
Group type: EXPERIMENTAL
Intervention: Group therapy intervention to decrease HIV-related risk behavior and trauma-related stress symptoms
Number of subjects: 167
Study 20585067 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy
Number of subjects: 65229
Study 18616068 — intervention group
Group type: EXPERIMENTAL
Intervention: Health services research (HSR)
Number of subjects: 0
Study 18616068 — intervention group
Group type: EXPERIMENTAL
Intervention: Chiropractic studies
Number of subjects: 0
Study 15987864 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (20 mg thiamine, 20 mg riboflavin, 25 mg B-6, 50 microg B-12, 500 mg C, 30 mg E, and 0.8 mg folic acid)
Number of subjects: 1078
Study 15987864 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation (30 mg beta-carotene plus 5000 IU preformed vitamin A)
Number of subjects: 1078
Study 15987864 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline systolic blood pressure (>120 mm Hg)
Number of subjects: 1078
Study 15987864 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher mid-upper arm circumference
Number of subjects: 1078
Study 11909925 — intervention group
Group type: EXPERIMENTAL
Intervention: Suggestion techniques during outpatient video EEG recording
Number of subjects: 30
Study 11909925 — intervention group
Group type: COMPARATOR
Intervention: No suggestion during outpatient video EEG recording
Number of subjects: 30
Study 11909925 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with a history of previous events in medical settings
Number of subjects: 30
Study 10702649 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine (Ach)
Number of subjects: 42
Study 10702649 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine
Number of subjects: 42
Study 10702649 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside
Number of subjects: 42
Study 10702649 — intervention group
Group type: COMPARATOR
Intervention: Reactive hyperemia
Number of subjects: 42
Study 8709296 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 days of abstinence
Number of subjects: 12
Study 8709296 — intervention group
Group type: COMPARATOR
Intervention: 0 days of abstinence
Number of subjects: 12
Study 1930765 — intervention group
Group type: EXPERIMENTAL
Intervention: narrative story
Number of subjects: 71
Study 1930765 — intervention group
Group type: EXPERIMENTAL
Intervention: method of loci
Number of subjects: 71
Study 1930765 — intervention group
Group type: COMPARATOR
Intervention: placebo training
Number of subjects: 71
Study 6178915 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 23
Study 6178915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30417332 — intervention group
Group type: COMPARATOR
Intervention: Telephone disclosure
Number of subjects: 1178
Study 30417332 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person disclosure
Number of subjects: 1178
Study 30417332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest counseling
Number of subjects: 1178
Study 30064474 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic gastrectomy (RG)
Number of subjects: 240
Study 30064474 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic gastrectomy (LG)
Number of subjects: 240
Study 27899067 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine (25 mg)
Number of subjects: 480
Study 27899067 — intervention group
Group type: EXPERIMENTAL
Intervention: Total effect of hydroxyzine
Number of subjects: 480
Study 27899067 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally estimated drug effect
Number of subjects: 480
Study 25298576 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional interferon (INF) α2a, 3MIU, S.C and ribavirin 1000 mg PO for 24 weeks in genotype 3 and 48 weeks in genotype 1 and 4 HCV patients.
Number of subjects: 60
Study 22670901 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid 100 mg twice daily
Number of subjects: 481
Study 22670901 — intervention group
Group type: EXPERIMENTAL
Intervention: Delamanid 200 mg twice daily
Number of subjects: 481
Study 22670901 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 481
Study 23120682 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin prophylaxis for 2 days
Number of subjects: 90
Study 23120682 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin prophylaxis for 5 days
Number of subjects: 90
Study 17885344 — intervention group
Group type: EXPERIMENTAL
Intervention: Heatwrap therapy in addition to oral analgesics
Number of subjects: 30
Study 17885344 — intervention group
Group type: COMPARATOR
Intervention: Oral analgesics (control group)
Number of subjects: 30
Study 16304476 — intervention group
Group type: EXPERIMENTAL
Intervention: PET-CT
Number of subjects: 41
Study 16304476 — intervention group
Group type: EXPERIMENTAL
Intervention: WB-MRI
Number of subjects: 41
Study 12183263 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin concentration at surgical closure < 0.5 mg/liter
Number of subjects: 10
Study 12183263 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamicin concentration at surgical closure ≥ 1.6 mg/liter
Number of subjects: 10
Study 12183263 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetes mellitus
Number of subjects: 10
Study 12183263 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of stoma
Number of subjects: 10
Study 12183263 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced age
Number of subjects: 10
Study 10728175 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for bulimia nervosa
Number of subjects: 94
Study 9815934 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin, 80 mg/m2, three times every 3 weeks
Number of subjects: 73
Study 9815934 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin, 375 mg/m2, three times every 3 weeks
Number of subjects: 73
Study 9815934 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiation therapy
Number of subjects: 73
Study 1952429 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine sulfate (0.025 mg/kg body weight)
Number of subjects: 7
Study 1952429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 7
Study 7281826 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg PETN
Number of subjects: 17
Study 7281826 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg PETN
Number of subjects: 17
Study 30698277 — intervention group
Group type: EXPERIMENTAL
Intervention: In-group targets
Number of subjects: 214
Study 30698277 — intervention group
Group type: EXPERIMENTAL
Intervention: Syrian targets
Number of subjects: 214
Study 30698277 — intervention group
Group type: COMPARATOR
Intervention: General reasoning about three groups
Number of subjects: 214
Study 30765429 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal glucose infusion (30 g glucose with 3 g 3-O-methylglucose)
Number of subjects: 20
Study 30765429 — intervention group
Group type: EXPERIMENTAL
Intervention: Distal glucose infusion (30 g glucose with 3 g 3-O-methylglucose)
Number of subjects: 20
Study 30765429 — intervention group
Group type: COMPARATOR
Intervention: Intravenous isoglycemic clamp studies
Number of subjects: 20
Study 28993935 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (n=39)
Number of subjects: 57
Study 28993935 — intervention group
Group type: COMPARATOR
Intervention: Non-surgical treatment (n=18)
Number of subjects: 57
Study 25350916 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes
Number of subjects: 0
Study 25350916 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetes (T2D)
Number of subjects: 0
Study 23828481 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial valve therapy (EBV)
Number of subjects: 169
Study 22089651 — intervention group
Group type: EXPERIMENTAL
Intervention: HFSC program (usual care plus HFSC)
Number of subjects: 27
Study 22089651 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 27
Study 19651956 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented all-polyethylene keeled glenoid component
Number of subjects: 25
Study 19651956 — intervention group
Group type: COMPARATOR
Intervention: Cemented all-polyethylene in-line three-pegged glenoid component
Number of subjects: 25
Study 17581811 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based program
Number of subjects: 419
Study 17581811 — intervention group
Group type: COMPARATOR
Intervention: Print materials
Number of subjects: 419
Study 15084552 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 100
Study 15084552 — intervention group
Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 100
Study 15941455 — intervention group
Group type: EXPERIMENTAL
Intervention: Day treatment programme (n = 21)
Number of subjects: 43
Study 15941455 — intervention group
Group type: COMPARATOR
Intervention: Traditional outpatient programme (n = 22)
Number of subjects: 43
Study 14528540 — intervention group
Group type: COMPARATOR
Intervention: Provider prompting intervention alone
Number of subjects: 1318
Study 14528540 — intervention group
Group type: COMPARATOR
Intervention: Provider prompting and tailored print materials
Number of subjects: 1318
Study 14528540 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider prompting, tailored print communications and tailored telephone counseling
Number of subjects: 1318
Study 8552798 — intervention group
Group type: EXPERIMENTAL
Intervention: Marketing strategy to promote research-based nursing care
Number of subjects: 20
Study 8552798 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard nursing care)
Number of subjects: 20
Study 1862125 — intervention group
Group type: EXPERIMENTAL
Intervention: PDWHF (purified platelet releasate)
Number of subjects: 0
Study 1862125 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 0
Study 6600426 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (2.6 g/day)
Number of subjects: 0
Study 6600426 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31447226 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate diet (CARB)
Number of subjects: 164
Study 31447226 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein diet (PROT)
Number of subjects: 164
Study 31447226 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsaturated fat diet (UNSAT)
Number of subjects: 164
Study 31447226 — intervention group
Group type: EXPERIMENTAL
Intervention: All diets (CARB, PROT, UNSAT)
Number of subjects: 164
Study 30578873 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (90 mg)
Number of subjects: 81
Study 30578873 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab (180 mg)
Number of subjects: 81
Study 30578873 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 81
Study 30578873 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab
Number of subjects: 81
Study 30578873 — intervention group
Group type: COMPARATOR
Intervention: Risankizumab and Ustekinumab
Number of subjects: 81
Study 28860170 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium carbonate‐bicarbonate buffer (SCB‐HCl; pH 7.4)
Number of subjects: 8
Study 28860170 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02% ethanol
Number of subjects: 8
Study 28860170 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% dimethyl sulfoxide (DMSO)
Number of subjects: 8
Study 28860170 — intervention group
Group type: COMPARATOR
Intervention: Control (lactated Ringer's)
Number of subjects: 8
Study 27298211 — intervention group
Group type: EXPERIMENTAL
Intervention: Online community intervention (n=99)
Number of subjects: 216
Study 27298211 — intervention group
Group type: COMPARATOR
Intervention: No online community (diary) condition (n=117)
Number of subjects: 216
Study 25927187 — intervention group
Group type: EXPERIMENTAL
Intervention: Training and support to deliver Positive Behaviour Support (PBS)
Number of subjects: 0
Study 25927187 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 23326011 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional endoscopic dilatation sinus surgery (FEDS)
Number of subjects: 24
Study 23326011 — intervention group
Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS)
Number of subjects: 24
Study 19776683 — intervention group
Group type: EXPERIMENTAL
Intervention: High group (target serum glucose concentration 9‐11 mmol/l)
Number of subjects: 68
Study 19776683 — intervention group
Group type: COMPARATOR
Intervention: Low group (target serum glucose concentration 5‐7 mmol/l)
Number of subjects: 68
Study 19776683 — intervention group
Group type: EXPERIMENTAL
Intervention: High group
Number of subjects: 68
Study 19776683 — intervention group
Group type: COMPARATOR
Intervention: Low group
Number of subjects: 68
Study 17276272 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthesia with intracameral nonpreserved lidocaine 0.5% (Group 2)
Number of subjects: 33
Study 17276272 — intervention group
Group type: COMPARATOR
Intervention: Topical anesthesia with 0.15 mL intracameral placebo (Group 1)
Number of subjects: 33
Study 17276272 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Group 1 and Group 2)
Number of subjects: 33
Study 15047656 — intervention group
Group type: EXPERIMENTAL
Intervention: HbA(1c) <8.4% (low HbA(1c) group)
Number of subjects: 39
Study 15047656 — intervention group
Group type: COMPARATOR
Intervention: HbA(1c) > or = 8.4% (high HbA(1c) group)
Number of subjects: 39
Study 12202468 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 57
Study 12202468 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo or calcium/vitamin D)
Number of subjects: 57
Study 9825370 — intervention group
Group type: EXPERIMENTAL
Intervention: Propafenone (2 mg/kg over 15 minutes followed by 10 mg/kg over the next 24 hours)
Number of subjects: 143
Study 9825370 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (300 mg intravenously over 1 hour, followed by 20 mg/kg over the next 24 hours, plus 1,800 mg/day orally, in 3 divided doses)
Number of subjects: 143
Study 9825370 — intervention group
Group type: COMPARATOR
Intervention: Placebo (equivalent amount of saline i.v. over 24 hours)
Number of subjects: 143
Study 7926530 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide/oxygen inhalation (n = 30)
Number of subjects: 89
Study 7926530 — intervention group
Group type: COMPARATOR
Intervention: Conventional intravenous sedation (pethidine 50 mg, midazolam 2.5 mg) (n = 29)
Number of subjects: 89
Study 7926530 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 89
Study 30010481 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10
Number of subjects: 372
Study 30010481 — intervention group
Group type: COMPARATOR
Intervention: US-RTX
Number of subjects: 372
Study 30010481 — intervention group
Group type: COMPARATOR
Intervention: EU-RTX
Number of subjects: 372
Study 30010481 — intervention group
Group type: COMPARATOR
Intervention: CT-P10 vs RTX
Number of subjects: 372
Study 30010481 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10 and RTX
Number of subjects: 372
Study 30010481 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P10, US-RTX, and EU-RTX
Number of subjects: 372
Study 27797437 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard and intense blood pressure goals (<120/80 mm Hg)
Number of subjects: 149
Study 24713048 — intervention group
Group type: EXPERIMENTAL
Intervention: TiZr implants
Number of subjects: 91
Study 24713048 — intervention group
Group type: COMPARATOR
Intervention: Ti Grade IV implants
Number of subjects: 91
Study 24006085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) alone
Number of subjects: 46
Study 24006085 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemtuzumab ozogamicin (GO) in combination with chemotherapy
Number of subjects: 46
Study 20868428 — intervention group
Group type: EXPERIMENTAL
Intervention: G1 - Sensodyne® (n=52)
Number of subjects: 120
Study 20868428 — intervention group
Group type: EXPERIMENTAL
Intervention: G2 - SensiKill® (n=62)
Number of subjects: 120
Study 20868428 — intervention group
Group type: EXPERIMENTAL
Intervention: G3 - Biosilicate® incorporated in a 1% water‐free‐gel (n=59)
Number of subjects: 120
Study 20868428 — intervention group
Group type: EXPERIMENTAL
Intervention: G4 - Biosilicate® mixed with distilled water at 1:10 ratio (n=59)
Number of subjects: 120
Study 19066100 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (within 7-24 hours)
Number of subjects: 500
Study 19066100 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (ultra-early stage < or = 7 h)
Number of subjects: 500
Study 19066100 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (delayed stage > 24 h)
Number of subjects: 500
Study 19066100 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 500
Study 16860796 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with unexplained recurrent miscarriage
Number of subjects: 37
Study 16860796 — intervention group
Group type: COMPARATOR
Intervention: Healthy fertile women
Number of subjects: 37
Study 12593901 — intervention group
Group type: EXPERIMENTAL
Intervention: Coil removal prior to treatment
Number of subjects: 126
Study 12593901 — intervention group
Group type: COMPARATOR
Intervention: No coil removal (Control)
Number of subjects: 126
Study 11131487 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (cisplatin-based)
Number of subjects: 19
Study 11131487 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone
Number of subjects: 19
Study 9069056 — intervention group
Group type: EXPERIMENTAL
Intervention: High-frequency jet ventilation
Number of subjects: 11
Study 9069056 — intervention group
Group type: COMPARATOR
Intervention: High-frequency positive pressure ventilation (Control)
Number of subjects: 11
Study 8350219 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (4.4 mg/L; final content, 11 mg/L)
Number of subjects: 52